Quantum BioPharma Beheer

Beheer criteriumcontroles 4/4

De CEO Quantum BioPharma is Zeeshan Saeed, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 599.87K, bestaande uit 37.1% salaris en 62.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.11% van de aandelen van het bedrijf, ter waarde $ 641.30K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 3.2 jaar.

Belangrijke informatie

Zeeshan Saeed

Algemeen directeur

US$599.9k

Totale compensatie

Percentage CEO-salaris	37.1%
Dienstverband CEO	3.3yrs
Eigendom CEO	6.1%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Zeeshan Saeed's beloning veranderd ten opzichte van Quantum BioPharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$600k	US$223k	-US$18m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$774k	US$239k	-US$27m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$30m
Dec 31 2021	US$1m	US$225k	-US$34m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$899k	US$212k	-US$28m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$2m	US$249k	-US$34m
Sep 30 2019	n/a	n/a	-US$38m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$503k	US$183k	-US$17m

Compensatie versus markt: De totale vergoeding ($USD 599.87K ) Zeeshan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Zeeshan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Zeeshan Saeed (54 yo)

3.3yrs

Tenure

US$599,873

Compensatie

Mr. Zeeshan Saeed serves as Executive Co-Chairman at FSD Pharma Inc. since May 24, 2018 and serves as its President since July 27, 2021 and Chief Executive Officer since June 29, 2023. He serves as Co-Chai...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zeeshan Saeed	Founder	3.3yrs	US$599.87k	6.11% $ 641.3k
Anthony Durkacz	Founder & Executive Co-Chairman	6.4yrs	US$599.87k	5.21% $ 547.2k
Donal Carroll	CFO & COO	3.3yrs	US$602.87k	4.31% $ 452.6k
Nathan Coyle	Controller	less than a year	US$178.21k	0.13% $ 13.7k
Lakshmi Kotra	CEO of Lucid & Director	3.2yrs	US$521.97k	1.14% $ 119.7k
Jason Sawyer	Head of Finance & Mergers and Acquisitions	less than a year	geen gegevens	geen gegevens
Maryann Adesso	Corporate Secretary	no data	geen gegevens	geen gegevens
Randell Mack	President of FSD BioSciences	3.7yrs	geen gegevens	geen gegevens
Andrzej Chruscinski	Vice President of Clinical & Scientific Affairs of Lucid	no data	US$110.30k	0% $ 0
Kevin Cassidy	Vice President of Quality-Lucid	no data	US$144.82k	geen gegevens

3.2yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QNTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zeeshan Saeed	Founder	3.5yrs	US$599.87k	6.11% $ 641.3k
Anthony Durkacz	Founder & Executive Co-Chairman	6.4yrs	US$599.87k	5.21% $ 547.2k
Lakshmi Kotra	CEO of Lucid & Director	2yrs	US$521.97k	1.14% $ 119.7k
Daniele Piomelli	Member of Research & Clinical Advisory Board	2.8yrs	geen gegevens	geen gegevens
Eleanor Fish	Member of Research & Clinical Advisory Board	3yrs	geen gegevens	geen gegevens
Hance Clarke	Member of Research & Clinical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Eric Hoskins	Independent Director	1.5yrs	geen gegevens	geen gegevens
Adnan Bashir	Independent Director	3.4yrs	US$139.37k	0.0075% $ 787.7
Peter Stys	Member of Research & Clinical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Shannon Dunn	Member of Research & Clinical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Albert Wong	Member of Research & Clinical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Joga Gobburu	Member of Regulatory Advisory Board	3yrs	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QNTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Quantum BioPharma Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Quantum BioPharma Ltd. Announces Executive Appointments

FSD Pharma Inc. Announces Board Changes

FSD Pharma Inc. Announces Change of CEO

FSD Pharma Inc. Announces CEO Changes

FSD Pharma Inc. Announces Board Changes

Founder recently bought US$328k worth of stock

Recent updates

New major risk - Financial position

Quantum BioPharma Regains Nasdaq Listing Compliance

Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next"

Quantum BioPharma Ltd. Announces Executive Appointments

New major risk - Financial position

FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

New major risk - Market cap size

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication

New major risk - Financial position

FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia

New minor risk - Shareholder dilution

FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd

FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 Forum

FSD Pharma Inc. has filed a Follow-on Equity Offering in the amount of $11.154232 million.

FSD Pharma Inc. Announces Board Changes

FSD Pharma Inc. Provides an Update Regarding Its Litigation with GBB Drink Lab, Inc

GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case

FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding

FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding

FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding

New major risk - Financial position

FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding

FSD Pharma Inc. Announces Change of CEO

FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza Bokhari

FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

FSD Pharma Inc. Announces CEO Changes

Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 Million

FSD Pharma Inc. Announces Board Changes

Founder recently bought US$328k worth of stock

FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

FSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic Pain

FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS

FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

FSD Pharma Inc. Announces Committee Appointments

FSD Pharma Announces Changes to the Board of Directors

Less than half of directors are independent

FSD Pharma Inc. Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

FSD Pharma Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

FSD Pharma receives Nasdaq minimum bid price deficiency notification

FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201

FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada

FSD Pharma Inc. Elects Fernando Cugliari as Director

FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate Updates

FSD Pharma Inc. Announces Dismissal of Derivative Complaint

FSD Pharma Inc., Annual General Meeting, Jun 23, 2022

High number of new and inexperienced directors

FSD Pharma Inc. Appoints David Allan and John Mcgraw to the Company's Advisory Board

FSD Pharma Inc. Announces Executive Appointments

An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million.

Founder recently bought US$40k worth of stock

Founder recently bought US$112k worth of stock

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)

FSD Pharma Inc. (CNSX:HUGE) entered into a definitive agreement to acquire Lucid Psycheceuticals Inc. for CAD 9.7 million.

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

FSD Pharma names Adnan Bashir as independent director

Independent Director has left the company

Independent Director has left the company

Independent Director has left the company

FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy

FSD Pharma submits FSD201 IND to treat gastrointestinal enteropathy in dogs

Independent Director has left the company

Chief Financial Officer has left the company

FSD Pharma appoints interim CFO